Publication: Why cure, why now?
Open/View Files
Date
2017
Authors
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
BMJ Publishing Group
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Kuritzkes, Daniel R. 2017. “Why cure, why now?” Journal of Medical Ethics 43 (2): 67-70. doi:10.1136/medethics-2015-103113. http://dx.doi.org/10.1136/medethics-2015-103113.
Research Data
Abstract
Combination antiretroviral therapy (cART) is highly effective at preventing morbidity and mortality due to infection with human immunodeficiency virus (HIV), but does not eradicate the virus. Consequently, cART must be administered life-long. Recent progress has stimulated research towards a cure of HIV infection. Approaches under investigation include hematopoietic stem cell transplantation, latency reactivating agents, immune based therapies, and cell-based therapies. Each of these approaches carries potential risks that must be weighed against the availability of safe and effective cART. Balancing the risks and benefits of this research poses unique challenges to potential study participants, clinicians and investigators.
Description
Other Available Sources
Keywords
HIV Infection and AIDS, Clinical trials, Ethics
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service